

Gout treatment may help prevent obesityrelated type 2 diabetes, suggests small NIH study

April 2 2019

The drug colchicine, used to treat the arthritic condition gout, could potentially reduce complications accompanying metabolic syndrome, a combination of high blood pressure, high blood sugar and other conditions that increase the risk of heart disease and type 2 diabetes, according to researchers at the National Institutes of Health. Their study appears in *Diabetes, Endocrinology, and Metabolism*.

Previous studies have indicated that the system-wide inflammation that occurs in obesity plays a role in the development of type 2 diabetes. In the current study, researchers led by Jack A. Yanovski, M.D., Ph.D., of NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) randomly assigned 21 <u>study participants</u> to received colchicine twice a day for 3 months, while 19 participants received a placebo. Colchicine suppresses a multi-protein complex called NLRP3, which triggers the inflammation seen in obesity.

Researchers looked at several measures that reflect how well insulin works in the body to clear sugar from the blood (<u>insulin resistance</u>). There was no difference between the two groups in insulin resistance determined by one measure of insulin use (the frequently sampled, insulin-modified intravenous glucose tolerance test). However, the colchicine group showed improvement on the Homeostatic Model Assessment of Insulin Resistance test, which also estimates how much <u>insulin</u> is needed to keep blood sugar at a normal level while fasting.



Those in the colchicine group also scored lower on a blood test of C-reactive protein and other tests that indicate inflammation. The authors concluded that larger studies are needed to determine if colchicine could prevent the development of type 2 diabetes in people with <u>metabolic</u> <u>syndrome</u>.

More information: Demidowich, AP et al. Effects of colchicine in adults with metabolic syndrome: a pilot randomized controlled trial. *Diabetes, Endocrinology, and Metabolism*.2019.

Provided by National Institutes of Health

Citation: Gout treatment may help prevent obesity-related type 2 diabetes, suggests small NIH study (2019, April 2) retrieved 6 May 2024 from <u>https://medicalxpress.com/news/2019-04-gout-treatment-obesity-related-diabetes-small.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.